{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T18:00:34Z","timestamp":1791568834373,"version":"4.3.4"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T00:00:00Z","timestamp":1763164800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T00:00:00Z","timestamp":1763164800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005713","name":"Technische Universit\u00e4t M\u00fcnchen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005713","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>\n                      Clinically accurate detection of prostate cancer (PCa) metastases is crucial for management of high-risk PCa patients scheduled for radical prostatectomy. We determine the safety and diagnostic accuracy of pre-operative\n                      <jats:sup>68<\/jats:sup>\n                      Ga-PSMA-11 PET\/CT imaging in newly diagnosed high-risk PCa and assess its impact on patient management.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Investigator-initiated prospective multi-center multinational single-arm open-label phase 1\/2 imaging trial (EuRadCT 2016\u2013001815-19). Patients with high-risk PCa scheduled for prostatectomy were enrolled at 9 institutions in Germany, Austria, and Switzerland to undergo\n                      <jats:sup>68<\/jats:sup>\n                      Ga-PSMA-11 PET\/CT for primary staging.\n                    <\/jats:p>\n                    <jats:p>\n                      The primary objectives were the evaluation of\n                      <jats:sup>68<\/jats:sup>\n                      Ga-PSMA-11 PET\/CT imaging to detect the primary tumor and lymph node disease and safety assessment. Secondary objectives included detection of distant metastases, correlation of\n                      <jats:sup>68<\/jats:sup>\n                      Ga-PSMA-11 uptake with Gleason Score, and determining the impact on clinical management. Impact of pre-operative\n                      <jats:sup>68<\/jats:sup>\n                      Ga-PSMA-11 PET\/CT imaging on target volume definition for radiation therapy was assessed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      173 patients underwent\n                      <jats:sup>68<\/jats:sup>\n                      Ga-PSMA-11 PET\/CT for primary staging. Histopathologic correlation was available in 139 patients (imaging dataset), with lymph node metastases in 55 patients (39.6%). 20 treatment-emergent AEs unrelated to the test item were reported in 14 of 173 (8.1%) patients and no SAE occurred. On a per-patient basis, sensitivity of\n                      <jats:sup>68<\/jats:sup>\n                      Ga-PSMA-11 PET for local disease was 0.971 (95% CI, 0.928\u20130.992). Sensitivity, specificity, PPV, NPV and accuracy to detect local lymph node disease on a per-patient basis were 0.400 (95% CI 0.271\u20130.529), 0.988 (95%CI 0.965\u20131.000), 0.957 (95% CI 0.873\u20131.000), 0.716 (95% CI 0.633\u20130.798) and 0.755 (95% CI 0.684\u20130.827), respectively. Considering the intrinsic PET resolution of 3\u20135\u00a0mm, the exclusion of lesions smaller than 3 or 5\u00a0mm on histopathology from the analysis led to increased sensitivity of 56.4% and 69.0%, respectively. Median SUVpeak of local disease was 6.4 (range 1.7\u201313.6), 8.4 (range 2.3\u201339.4), 10.7 (range 5.6\u201323.0), and 13.4 (range 3.8\u201356.9) for Gleason Score 7a, 7b, 8 and 9, respectively. Based on the results of\n                      <jats:sup>68<\/jats:sup>\n                      Ga-PSMA-11 PET\/CT, surgical intervention was canceled in 23 patients (13.2%).\n                      <jats:sup>68<\/jats:sup>\n                      Ga-PSMA-11 PET\/CT resulted in a change of target volume delineation for radiation therapy planning in 29 patients (20.9%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      In high-risk primary PCa,\n                      <jats:sup>68<\/jats:sup>\n                      Ga-PSMA-11 is safe and effective in local staging, resulting in changes in both surgical and radiation management. Moreover,\n                      <jats:sup>68<\/jats:sup>\n                      Ga-PSMA-11 uptake is positively correlated with tumor grade and its efficacy is dependent on the size of nodal lesions.\n                      <jats:sup>68<\/jats:sup>\n                      Ga-PSMA-11 PET\/CT will be highly impactful in the management of newly diagnosed high risk prostate cancer patients.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Funding<\/jats:title>\n                    <jats:p>The study was funded by the German Cancer Consortium (DKTK).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00259-025-07540-4","type":"journal-article","created":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T07:59:20Z","timestamp":1763193560000},"page":"2994-3006","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The German Cancer Consortium (DKTK) multi-center prospective phase 1\/2 68Ga-PSMA-11 PET-imaging trial in newly-diagnosed high-risk prostate cancer: Safety and diagnostic accuracy compared to histopathology and their impact on patient management"],"prefix":"10.1007","volume":"53","author":[{"given":"Frederik L.","family":"Giesel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan A.","family":"Koerber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Hadaschik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selina","family":"Kiefer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Schwarzenboeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kambiz","family":"Rahbar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorsten","family":"Derlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph A.","family":"Grott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Heck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cordula","family":"Jilg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp T.","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juri","family":"Ruf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joerg","family":"Kotzerke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"la Foug\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald","family":"Reischl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Virgolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene A.","family":"Burger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theo","family":"Lorenzini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Werner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albrecht","family":"Stenzinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Schwamborn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan Philipp","family":"Radtke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Hohenfellner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juergen","family":"Debus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang A.","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Haberkorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Kopka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2130-644X","authenticated-orcid":false,"given":"Matthias","family":"Eiber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"68Ga-PSMA-11 DKTK trial contributors","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ursula","family":"Sahm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffen","family":"Rausch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemens","family":"Decristofero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Uprimny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianpaolo","family":"di Santo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Rangger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerd","family":"Wunderlich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Huber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Sommer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anass","family":"Johayem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp A.","family":"Kaufmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Eberli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Tonndorf-Martini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"Muehlhauser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemens","family":"Kratochwil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Schubert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Kiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ute","family":"Hennrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Choyke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus","family":"Zippel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Otmar","family":"Wiestler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Baumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Reil-Held","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volker","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Meese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Maurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Remke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Watzlowik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franz","family":"Gildehaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olaf","family":"Prante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"H\u00f6pping","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gesine","family":"Kabuss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Gschwend","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Kienzle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,15]]},"reference":[{"key":"7540_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"CA Cancer J Clin"},{"key":"7540_CR2","unstructured":"National Comprehensive Cancer Network (NCCN). Prostate cancer (Version 3.2024). 2024. https:\/\/pubmed.ncbi.nlm.nih.gov\/38626801\/"},{"key":"7540_CR3","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.crad.2007.05.022","volume":"63","author":"AM H\u00f6vels","year":"2008","unstructured":"H\u00f6vels AM, Heesakkers RAM, Adang EM, Jager GJ, Strum S, Hoogeveen YL, et al. The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. Clin Radiol. 2008;63:387\u201395. https:\/\/doi.org\/10.1016\/j.crad.2007.05.022.","journal-title":"Clin Radiol"},{"key":"7540_CR4","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1016\/j.eururo.2011.11.008","volume":"61","author":"A Briganti","year":"2012","unstructured":"Briganti A, Abdollah F, Nini A, Suardi N, Gallina A, Capitanio U, et al. Performance characteristics of computed tomography in detecting lymph node metastases in contemporary patients with prostate cancer treated with extended pelvic lymph node dissection. Eur Urol. 2012;61:1132\u20138. https:\/\/doi.org\/10.1016\/j.eururo.2011.11.008.","journal-title":"Eur Urol"},{"key":"7540_CR5","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1007\/s00259-016-3419-0","volume":"43","author":"A Afshar-Oromieh","year":"2016","unstructured":"Afshar-Oromieh A, Hetzheim H, K\u00fcbler W, Kratochwil C, Giesel FL, Hope TA, et al. Radiation dosimetry of (68)Ga-PSMA-11 (HBED-CC) and preliminary evaluation of optimal imaging timing. Eur J Nucl Med Mol Imaging. 2016;43:1611\u201320. https:\/\/doi.org\/10.1007\/s00259-016-3419-0.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7540_CR6","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1007\/s00259-012-2298-2","volume":"40","author":"A Afshar-Oromieh","year":"2013","unstructured":"Afshar-Oromieh A, Malcher A, Eder M, Eisenhut M, Linhart HG, Hadaschik BA, et al. PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging. 2013;40:486\u201395. https:\/\/doi.org\/10.1007\/s00259-012-2298-2.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7540_CR7","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1021\/bc200279b","volume":"23","author":"M Eder","year":"2012","unstructured":"Eder M, Sch\u00e4fer M, Bauder-W\u00fcst U, Hull W-E, W\u00e4ngler C, Mier W, et al. 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. Bioconjug Chem. 2012;23:688\u201397. https:\/\/doi.org\/10.1021\/bc200279b.","journal-title":"Bioconjug Chem"},{"key":"7540_CR8","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s00259-014-2949-6","volume":"42","author":"A Afshar-Oromieh","year":"2015","unstructured":"Afshar-Oromieh A, Avtzi E, Giesel FL, Holland-Letz T, Linhart HG, Eder M, et al. The diagnostic value of PET\/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42:197\u2013209. https:\/\/doi.org\/10.1007\/s00259-014-2949-6.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7540_CR9","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s00259-013-2525-5","volume":"41","author":"A Afshar-Oromieh","year":"2014","unstructured":"Afshar-Oromieh A, Zechmann CM, Malcher A, Eder M, Eisenhut M, Linhart HG, et al. Comparison of PET imaging with a 68Ga-labelled PSMA ligand and 18F-choline-based PET\/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2014;41:11\u201320. https:\/\/doi.org\/10.1007\/s00259-013-2525-5.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7540_CR10","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1001\/jamaoncol.2019.0096","volume":"5","author":"WP Fendler","year":"2019","unstructured":"Fendler WP, Calais J, Eiber M, Flavell RR, Mishoe A, Feng FY, et al. Assessment of 68Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer: a prospective single-arm clinical trial. JAMA Oncol. 2019;5:856\u201363. https:\/\/doi.org\/10.1001\/jamaoncol.2019.0096.","journal-title":"JAMA Oncol"},{"key":"7540_CR11","unstructured":"FDA. FDA Approves First PSMA-Targeted PET Imaging Drug for Men with Prostate Cancer. 2020. https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-second-psma-targeted-pet-imaging-drug-men-prostate-cancer"},{"key":"7540_CR12","unstructured":"EAU Guidelines on Prostate Cancer. Edn. presented at the EAU Annual Congress Milan. 2023. https:\/\/pubmed.ncbi.nlm.nih.gov\/38614820\/"},{"key":"7540_CR13","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1007\/s00259-022-06089-w","volume":"50","author":"WP Fendler","year":"2023","unstructured":"Fendler WP, Eiber M, Beheshti M, Bomanji J, Calais J, Ceci F, et al. PSMA PET\/CT: joint EANM procedure guideline\/SNMMI procedure standard for prostate cancer imaging 2.0. Eur J Nucl Med Mol Imaging. 2023;50:1466\u201386. https:\/\/doi.org\/10.1007\/s00259-022-06089-w.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7540_CR14","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.eururo.2023.06.018","volume":"84","author":"DS Surasi","year":"2023","unstructured":"Surasi DS, Eiber M, Maurer T, Preston MA, Helfand BT, Josephson D, et al. Diagnostic performance and safety of positron emission tomography with 18F-rhPSMA-7.3 in patients with newly diagnosed unfavourable intermediate- to very-high-risk prostate cancer: results from a phase 3, prospective, multicentre study (LIGHTHOUSE). Eur Urol. 2023;84:361\u201370. https:\/\/doi.org\/10.1016\/j.eururo.2023.06.018.","journal-title":"Eur Urol"},{"key":"7540_CR15","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1007\/s00259-016-3573-4","volume":"44","author":"FL Giesel","year":"2017","unstructured":"Giesel FL, Hadaschik B, Cardinale J, Radtke J, Vinsensia M, Lehnert W, et al. F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients. Eur J Nucl Med Mol Imaging. 2017;44:678\u201388. https:\/\/doi.org\/10.1007\/s00259-016-3573-4.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7540_CR16","doi-asserted-by":"publisher","first-page":"362","DOI":"10.2967\/jnumed.118.212233","volume":"60","author":"FL Giesel","year":"2019","unstructured":"Giesel FL, Knorr K, Spohn F, Will L, Maurer T, Flechsig P, et al. Detection efficacy of (18)F-PSMA-1007 PET\/CT in 251 patients with biochemical recurrence of prostate cancer after radical prostatectomy. J Nucl Med. 2019;60:362\u20138. https:\/\/doi.org\/10.2967\/jnumed.118.212233.","journal-title":"J Nucl Med"},{"key":"7540_CR17","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1007\/s00259-015-3188-1","volume":"43","author":"F Sterzing","year":"2016","unstructured":"Sterzing F, Kratochwil C, Fiedler H, Katayama S, Habl G, Kopka K, et al. (68)Ga-PSMA-11 PET\/CT: a new technique with high potential for the radiotherapeutic management of prostate cancer patients. Eur J Nucl Med Mol Imaging. 2016;43:34\u201341. https:\/\/doi.org\/10.1007\/s00259-015-3188-1.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7540_CR18","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1016\/s1470-2045(19)30415-2","volume":"20","author":"J Calais","year":"2019","unstructured":"Calais J, Ceci F, Eiber M, Hope TA, Hofman MS, Rischpler C, et al. (18)F-fluciclovine PET-CT and (68)Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial. Lancet Oncol. 2019;20:1286\u201394. https:\/\/doi.org\/10.1016\/s1470-2045(19)30415-2.","journal-title":"Lancet Oncol"},{"key":"7540_CR19","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/s0140-6736(20)30314-7","volume":"395","author":"MS Hofman","year":"2020","unstructured":"Hofman MS, Lawrentschuk N, Francis RJ, Tang C, Vela I, Thomas P, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet. 2020;395:1208\u201316. https:\/\/doi.org\/10.1016\/s0140-6736(20)30314-7.","journal-title":"Lancet"},{"key":"7540_CR20","doi-asserted-by":"publisher","first-page":"469","DOI":"10.2967\/jnumed.117.198119","volume":"59","author":"M Eiber","year":"2018","unstructured":"Eiber M, Herrmann K, Calais J, Hadaschik B, Giesel FL, Hartenbach M, et al. Prostate cancer molecular imaging standardized evaluation (PROMISE): proposed mitnm classification for the interpretation of PSMA-ligand PET\/CT. J Nucl Med. 2018;59:469\u201378. https:\/\/doi.org\/10.2967\/jnumed.117.198119.","journal-title":"J Nucl Med"},{"key":"7540_CR21","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.2967\/jnumed.117.190314","volume":"58","author":"SA Koerber","year":"2017","unstructured":"Koerber SA, Utzinger MT, Kratochwil C, Kesch C, Haefner MF, Katayama S, et al. (68)Ga-PSMA-11 PET\/CT in newly diagnosed carcinoma of the prostate: correlation of intraprostatic PSMA uptake with several clinical parameters. J Nucl Med. 2017;58:1943\u20138. https:\/\/doi.org\/10.2967\/jnumed.117.190314.","journal-title":"J Nucl Med"},{"key":"7540_CR22","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1016\/j.juro.2015.12.025","volume":"195","author":"T Maurer","year":"2016","unstructured":"Maurer T, Gschwend JE, Rauscher I, Souvatzoglou M, Haller B, Weirich G, et al. Diagnostic efficacy of (68)gallium-PSMA positron emission tomography compared to conventional imaging for lymph node staging of 130 consecutive patients with intermediate to high risk prostate cancer. J Urol. 2016;195:1436\u201343. https:\/\/doi.org\/10.1016\/j.juro.2015.12.025.","journal-title":"J Urol"},{"key":"7540_CR23","doi-asserted-by":"publisher","first-page":"2491","DOI":"10.1056\/NEJMoa022749","volume":"348","author":"MG Harisinghani","year":"2003","unstructured":"Harisinghani MG, Barentsz J, Hahn PF, Deserno WM, Tabatabaei S, van de Kaa CH, et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med. 2003;348:2491\u20139. https:\/\/doi.org\/10.1056\/NEJMoa022749.","journal-title":"N Engl J Med"},{"key":"7540_CR24","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1001\/jamaoncol.2021.3771","volume":"7","author":"TA Hope","year":"2021","unstructured":"Hope TA, Eiber M, Armstrong WR, Juarez R, Murthy V, Lawhn-Heath C, et al. Diagnostic accuracy of 68Ga-PSMA-11 PET for pelvic nodal metastasis detection prior to radical prostatectomy and pelvic lymph node dissection: a multicenter prospective phase 3 imaging trial. JAMA Oncol. 2021;7:1635\u201342. https:\/\/doi.org\/10.1001\/jamaoncol.2021.3771.","journal-title":"JAMA Oncol"},{"key":"7540_CR25","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1097\/ju.0000000000001698","volume":"206","author":"KJ Pienta","year":"2021","unstructured":"Pienta KJ, Gorin MA, Rowe SP, Carroll PR, Pouliot F, Probst S, et al. A phase 2\/3 prospective multicenter study of the diagnostic accuracy of prostate specific membrane antigen PET\/CT with (18)F-DCFPyL in prostate cancer patients (OSPREY). J Urol. 2021;206:52\u201361. https:\/\/doi.org\/10.1097\/ju.0000000000001698.","journal-title":"J Urol"},{"key":"7540_CR26","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s40644-020-0290-9","volume":"20","author":"LJ Petersen","year":"2020","unstructured":"Petersen LJ, Zacho HD. PSMA PET for primary lymph node staging of intermediate and high-risk prostate cancer: an expedited systematic review. Cancer Imaging. 2020;20:10. https:\/\/doi.org\/10.1186\/s40644-020-0290-9.","journal-title":"Cancer Imaging"},{"key":"7540_CR27","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1503\/cmaj.050090","volume":"174","author":"AW Rutjes","year":"2006","unstructured":"Rutjes AW, Reitsma JB, Di Nisio M, Smidt N, van Rijn JC, Bossuyt PM. Evidence of bias and variation in diagnostic accuracy studies. CMAJ. 2006;174:469\u201376. https:\/\/doi.org\/10.1503\/cmaj.050090.","journal-title":"CMAJ"},{"key":"7540_CR28","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.2214\/ajr.167.6.8956585","volume":"167","author":"GJ Jager","year":"1996","unstructured":"Jager GJ, Barentsz JO, Oosterhof GO, Witjes JA, Ruijs SJ. Pelvic adenopathy in prostatic and urinary bladder carcinoma: MR imaging with a three-dimensional TI-weighted magnetization-prepared-rapid gradient-echo sequence. Am J Roentgenol. 1996;167:1503\u20137. https:\/\/doi.org\/10.2214\/ajr.167.6.8956585.","journal-title":"Am J Roentgenol"},{"key":"7540_CR29","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.eururo.2015.12.053","volume":"70","author":"M Eiber","year":"2016","unstructured":"Eiber M, Weirich G, Holzapfel K, Souvatzoglou M, Haller B, Rauscher I, et al. Simultaneous (68)Ga-PSMA HBED-CC PET\/MRI improves the localization of primary prostate cancer. Eur Urol. 2016;70:829\u201336. https:\/\/doi.org\/10.1016\/j.eururo.2015.12.053.","journal-title":"Eur Urol"},{"key":"7540_CR30","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/1078-1439(95)00002-y","volume":"1","author":"GL Wright Jr.","year":"1995","unstructured":"Wright GL Jr., Haley C, Beckett ML, Schellhammer PF. Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues. Urol Oncol. 1995;1:18\u201328. https:\/\/doi.org\/10.1016\/1078-1439(95)00002-y.","journal-title":"Urol Oncol"},{"key":"7540_CR31","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.2967\/jnumed.116.172627","volume":"57","author":"WP Fendler","year":"2016","unstructured":"Fendler WP, Schmidt DF, Wenter V, Thierfelder KM, Zach C, Stief C, et al. 68Ga-PSMA PET\/CT detects the location and extent of primary prostate cancer. J Nucl Med. 2016;57:1720\u20135. https:\/\/doi.org\/10.2967\/jnumed.116.172627.","journal-title":"J Nucl Med"},{"key":"7540_CR32","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1007\/s00259-018-3979-2","volume":"45","author":"DA Pizzuto","year":"2018","unstructured":"Pizzuto DA, M\u00fcller J, M\u00fchlematter U, Rupp NJ, T\u00f6pfer A, Mortezavi A, et al. The central zone has increased 68Ga-PSMA-11 uptake: \u201cMickey Mouse ears\u201d can be hot on 68Ga-PSMA-11 PET. Eur J Nucl Med Mol Imaging. 2018;45:1335\u201343. https:\/\/doi.org\/10.1007\/s00259-018-3979-2.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7540_CR33","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.2967\/jnumed.117.190827","volume":"58","author":"WP Fendler","year":"2017","unstructured":"Fendler WP, Calais J, Allen-Auerbach M, Bluemel C, Eberhardt N, Emmett L, et al. (68)Ga-PSMA-11 PET\/CT interobserver agreement for prostate cancer assessments: an international multicenter prospective study. J Nucl Med. 2017;58:1617\u201323. https:\/\/doi.org\/10.2967\/jnumed.117.190827.","journal-title":"J Nucl Med"},{"key":"7540_CR34","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1007\/s00259-016-3435-0","volume":"43","author":"T Pyka","year":"2016","unstructured":"Pyka T, Okamoto S, Dahlbender M, Tauber R, Retz M, Heck M, et al. Comparison of bone scintigraphy and (68)Ga-PSMA PET for skeletal staging in prostate cancer. Eur J Nucl Med Mol Imaging. 2016;43:2114\u201321. https:\/\/doi.org\/10.1007\/s00259-016-3435-0.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7540_CR35","first-page":"447","volume":"56","author":"W Langsteger","year":"2012","unstructured":"Langsteger W, Haim S, Knauer M, Waldenberger P, Emmanuel K, Loidl W, et al. Imaging of bone metastases in prostate cancer: an update. Q J Nucl Med Mol Imaging. 2012;56:447\u201358.","journal-title":"Q J Nucl Med Mol Imaging"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07540-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-025-07540-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07540-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T01:26:27Z","timestamp":1774401987000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-025-07540-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,15]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["7540"],"URL":"https:\/\/doi.org\/10.1007\/s00259-025-07540-4","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,15]]},"assertion":[{"value":"30 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Approved by the IRB at the main site in Heidelberg, following subsequent approval at all participating sites.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All patients have been consented for the trial.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Permission to published was included in the ICF and granted by DKTK.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"EudraCT-Nr. 2016\u2013001815-19,ClinicalTrials.gov ID NCT03362359.DRKS ID DRKS00013701.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Study registrations"}},{"value":"KK is a co-inventor of PSMA-617 and PSMA-1007 and is\/was a member of the scientific advisory board of Telix and Fuzionaire Tx. TD reports personal fees from ABX-CRO and Novartis Radiopharmaceuticals. KH reports personal fees from Advanced Accelerator Applications, a Novartis company, Amgen, AstraZeneca, Bain Capital, Bayer, Boston Scientific, Convergent, Curium, Debiopharm, EcoR1, Fusion, GE Healthcare, Immedica, Isotopen Technologien M\u00fcnchen, Janssen, Merck, Molecular Partners, NVision, POINT Biopharma, Pfizer, Radiopharm Theranostics, Rhine Pharma, Siemens Healthineers, Sofie Biosciences, Telix, and Theragnostics, ymabs, institutional grants from Novartis and Sophie Biosciences, honoraria from PeerVoice, support for travel from Janssen, stock\/stock options from Sofie Biosciences, Pharma15, NVision, Convergent, Aktis Oncology, AdvanCell. JC reports stocks from Telix radiopharmaceuticals and Fuzionaire Theranostics. SK reports research grants from Vieway, honoraria from IBA Dosimetry, Think Wired!, PET e.v., Streamed up. SS reports honoraria from ABX-CRO, Oncobeta and AstraZeneca, grants from Novartis. AS honoraria from Agilent, Aignostics, Amgen, Astellas, Astra Zeneca, Bayer, BMS, Eli Lilly, Illumina, Incyte, Janssen, MSD, Novartis, Pfizer, Qlucore, QuiP, Roche, Sanofi, Seagen, Servier, Takeda, Thermo Fisher and grants from Bayer, BMS, Chugai, Incyte, MSD. WAW is an associate editor of EJNMMI. He has received research support from BED, ITM, Novartis, Pentixapharm, Ratio Therapeutics, and Rayzebio. He serves on advisory boards for Curium, ITM, Novartis, Ornano Med, Ratio Therapeutics, Imuveo. BH reports grants from Novartis, BMS, royalties from Uromed, honoraria from Janssen, Bayer, Novartis, BMS, ABX, Merck, Onkowissen, Accord Healthcare, AstraZeneca, MSD, Pfizer, Amgen, Astellas, Lightpoint medical, Point Biopharma, Ipsen, Telix. ME reports fees from Blue Earth Diagnostics Ltd. (consultant, research funding), Novartis\/AAA (consultant, speaker), Telix (consultant), Bayer (consultant, research funding), RayzeBio (consultant), Point Biopharma (consultant), Eckert-Ziegler (speaker) and Janssen Pharmaceuticals (consultant, speakers bureau), Parexel (image review) and Bioclinica (image review) outside the submitted work and a patent application for rhPSMA. He and other inventors are entitled to royalties on sales of POSLUMA\u00ae. ME serves on advisory boards and\/or steering comittes for Novartis, Blue Earth Diagnostics and Telix.\u00a0FLG reports being an inventor of FAP-ligands (FAPI-46 and FAPI-74), PSMA-1007, and PSMA-GCK01, as well as an advisor at ABX GmbH, Telix Pharmaceuticals Ltd., SOFIE Biosciences, Alfafusion, and Rhine Pharma.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}